AstraZeneca ((AZN)), Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a significant advancement for cancer treatment, AstraZeneca and Eli Lilly are collaborating on a Phase 3 clinical study titled ‘SUNRAY-02’. This study aims to evaluate the efficacy and safety of olomorasib in combination with standard immunotherapy for patients with resected or unresectable KRAS G12C-mutant non-small cell lung cancer (NSCLC). The study’s primary objective is to determine if olomorasib, when combined with pembrolizumab or durvalumab, is more effective than the current standard of care treatments.
The study tests olomorasib, an oral drug, in combination with pembrolizumab or durvalumab, both administered intravenously. These combinations are compared against placebo groups to assess their effectiveness in treating NSCLC.
This randomized, double-blind, placebo-controlled study involves parallel assignment of participants to different treatment groups. The primary purpose is treatment-focused, ensuring that neither participants nor investigators know which treatment is being administered, maintaining objectivity in results.
The study began on March 18, 2025, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 22, 2025, indicating ongoing recruitment and progress.
This study could significantly impact the stock performance of AstraZeneca and Eli Lilly, as successful results may enhance their market positions in the oncology sector. Investors will be keenly watching for updates, especially given the competitive landscape of cancer treatments.
The study is currently ongoing, and further details can be accessed on the ClinicalTrials portal.